Blackstone, Carlyle consider joint bid for Novartis generics unit – Bloomberg News

Reuters

– Private equity firms Blackstone Inc and Carlyle Group Inc are in talks about potentially teaming up on a bid for Swiss drugmaker Novartis’ generics unit, Bloomberg News reported on Tuesday, citing people with knowledge of the matter.

The companies have been studying the merits of a joint offer for the Sandoz business, which could be valued at around $25 billion, according to the report.

Other buyout firms are also considering bids, Bloomberg News said.

Related News:   New Jersey Gas Station Tipping, Do You Do It?

Last year, Novartis announced a strategic review of its generics unit, Sandoz, after years of revamping the business, as price pressures mount in the off-patent drug sector.


Carlyle and Novartis declined to comment, while Blackstone did not immediately respond to a Reuters request for comment.


(Reporting by Dania Nadeem in Bengaluru; Editing by Shounak Dasgupta)

tagreuters.com2022binary_LYNXMPEI101SE-BASEIMAGE

tagreuters.com2022binary_LYNXMPEI101SF-BASEIMAGE

You appear to be using an ad blocker

Shore News Network is a free website that does not use paywalls or charge for access to original, breaking news content. In order to provide this free service, we rely on advertisements. Please support our journalism by disabling your ad blocker for this website.